Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „saxagliptin“
Suchtreffer
Begriffe & Kennungen
Komboglyze · 4.5 · 7 Glycaemic control should be carefully assessed when saxagliptin is used concomitantly with a potent CYP3A4 i
Eintrag öffnenKomboglyze · 4.5 · Co-administration of multiple doses of saxagliptin (2.5 mg twice daily) and metformin (1,000 mg twice daily) d
Eintrag öffnenKomboglyze · 4.5 · Concomitant administration of saxagliptin with the moderate inhibitor of CYP3A4/5 diltiazem, increased the Cma
Eintrag öffnenKomboglyze · 4.5 · Concomitant administration of saxagliptin with the potent CYP3A4/5 inducer rifampicin, reduced Cmax and AUC of
Eintrag öffnenKomboglyze · 4.5 · Concomitant administration of saxagliptin with the potent inhibitor of CYP3A4/5 ketoconazole, increased the Cm
Eintrag öffnenKomboglyze · 4.5 · Saxagliptin Clinical data described below suggest that the risk for clinically meaningful interactions with co
Eintrag öffnenKomboglyze · 4.5 · The co-administration of saxagliptin and CYP3A4/5 inducers, other than rifampicin (such as carbamazepine, dexa
Eintrag öffnenKomboglyze · 4.5 · The effects of smoking, diet, herbal products, and alcohol use on the pharmacokinetics of saxagliptin have not
Eintrag öffnenKomboglyze · 4.5 · The metabolism of saxagliptin is primarily mediated by cytochrome P450 3A4/5 (CYP3A4/5). In in vitro studies,
Eintrag öffnenKomboglyze · 4.8 · 10 Decreased lymphocyte counts were reported in 0.5% of saxagliptin-treated patients and 0.4% of placebo-treat
Eintrag öffnenKomboglyze · 4.8 · Hospitalisation for heart failure, occurred at a greater rate in the saxagliptin group (3.5%) compared with th
Eintrag öffnenKomboglyze · 4.8 · In a pooled analysis of 1,681 patients with type 2 diabetes, including 882 patients treated with saxagliptin 5
Eintrag öffnenKomboglyze · 4.8 · SAVOR trial results The SAVOR trial included 8240 patients treated with saxagliptin 5 mg or 2.5 mg once daily
Eintrag öffnenKomboglyze · 4.8 · Saxagliptin Summary of the safety profile There were 4,148 patients with type 2 diabetes, including 3,021 pati
Eintrag öffnenKomboglyze · 4.8 · System organ class Frequency of adverse reactions by treatment regimen Adverse reaction Saxagliptin with metfo
Eintrag öffnenKomboglyze · 4.8 · Tabulated list of adverse reactions Adverse reactions reported in ≥ 5% of patients treated with saxagliptin 5
Eintrag öffnenKomboglyze · 4.8 · The incidence of adjudicated pancreatitis events was 0.3% in both saxagliptin-treated patients and placebo-tre
Eintrag öffnenKomboglyze · 4.8 · The incidence of hypersensitivity reactions was 1.1% in both saxagliptin-treated patients and placebo- treated
Eintrag öffnenOnglyza · 4.5 · 5 Concomitant administration of saxagliptin with the moderate inhibitor of CYP3A4/5 diltiazem, increased the C
Eintrag öffnenOnglyza · 4.5 · Concomitant administration of saxagliptin with the potent CYP3A4/5 inducer rifampicin, reduced Cmax and AUC of
Eintrag öffnen